Roche (RHHBY) News Today $41.83 +0.09 (+0.22%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in AdultsMarch 3 at 12:52 PM | finance.yahoo.comFDA Approves Genentech's TNKase® in Acute Ischemic Stroke in AdultsMarch 3 at 11:45 AM | businesswire.comF. Hoffmann-La Roche Digital Transformation Analysis Report 2024: Accelerators, Incubators, and Innovation ProgramsMarch 3 at 6:03 AM | globenewswire.comRoche’s Genetech announces data from Phase III OUtMATCH studyMarch 3 at 2:42 AM | markets.businessinsider.comPhase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food AllergiesMarch 2 at 5:00 PM | businesswire.comPhase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergiesMarch 2 at 5:00 PM | globenewswire.comRhumbline Advisers Sells 8,857 Shares of Roche Holding AG (OTCMKTS:RHHBY)Rhumbline Advisers trimmed its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 8.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,878 shares of the companMarch 2 at 3:04 AM | marketbeat.comRoche Holding AG (OTCMKTS:RHHBY) Short Interest UpdateRoche Holding AG (OTCMKTS:RHHBY - Get Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 2,068,200 shares, a decrease of 45.0% from the January 31st total of 3,761,500 shares. Based on an average daily trading volume, of 2,515,400 shares, the days-to-cover ratio is currently 0.8 days.March 2 at 2:03 AM | marketbeat.comRoche gets positive EU regulatory opinion for ColumviMarch 1 at 1:43 PM | msn.comCHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphomaFebruary 28 at 12:43 PM | finance.yahoo.comRoche says CHMP recommends EU approval of Columvi combinationFebruary 28 at 12:43 PM | markets.businessinsider.comCHMP recommends EU approval of Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphomaFebruary 28 at 8:15 AM | globenewswire.comImmune-Onc Therapeutics Announces First Patient Dosed with IO-108 in a Randomized Global Phase 1b/2 Study of First-Line Treatment of Advanced Liver Cancer in Clinical Collaboration with RocheFebruary 27, 2025 | businesswire.comRoche: Sustainable Sales Growth, Margin Leverage, And Supportive Late-Stage PipelineFebruary 26, 2025 | seekingalpha.comRoche: Balanced Between Catalysts And HeadwindsFebruary 26, 2025 | seekingalpha.comViking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval? (RHHBY)Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.February 26, 2025 | marketbeat.comF. Hoffmann-La Roche Ltd: Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technologyFebruary 20, 2025 | finanznachrichten.deRoche unveils its breakthrough proprietary SBX technologyFebruary 20, 2025 | markets.businessinsider.comRoche unveils a new class of next-generation sequencing with its novel sequencing by expansion technologyFebruary 20, 2025 | globenewswire.comKornitzer Capital Management Inc. KS Decreases Stock Holdings in Roche Holding AG (OTCMKTS:RHHBY)Kornitzer Capital Management Inc. KS lowered its stake in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 33.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,239 sharesFebruary 19, 2025 | marketbeat.comYemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with RocheFebruary 18, 2025 | businesswire.comRoche Holding AG (OTCMKTS:RHHBY) Receives Consensus Rating of "Hold" from BrokeragesShares of Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) have been given an average rating of "Hold" by the six ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating, one has given a buyFebruary 15, 2025 | marketbeat.comRoche upgraded by UBS to buy on growth outlookFebruary 13, 2025 | msn.comUBS lifts Roche stock rating to Buy, raises target to CHF338February 13, 2025 | msn.comRoche upgraded to Buy from Neutral at UBSFebruary 13, 2025 | markets.businessinsider.comF. Hoffmann-La Roche Ltd: FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)February 13, 2025 | finanznachrichten.deRoche initiated with an Equal Weight at Morgan StanleyFebruary 12, 2025 | markets.businessinsider.comRoche announces FDA approves Evrysdi tablet to treat SMAFebruary 12, 2025 | markets.businessinsider.comFDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)February 12, 2025 | businesswire.comFDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)February 12, 2025 | globenewswire.comRoche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of "Hold" from AnalystsRoche Holding AG (OTCMKTS:RHHBY - Get Free Report) has earned an average rating of "Hold" from the five brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy ratingFebruary 12, 2025 | marketbeat.comRoche (OTCMKTS:RHHBY) Coverage Initiated by Analysts at Morgan StanleyMorgan Stanley assumed coverage on Roche in a research report on Wednesday. They set an "equal weight" rating on the stock.February 12, 2025 | marketbeat.comIs Roche Holding AG (RHHBY) The Best Annual Dividend Stock To Buy Now?February 10, 2025 | insidermonkey.comGenentech publishes REGENCY trial data in the New England Journal of MedicineFebruary 7, 2025 | markets.businessinsider.comNew England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus NephritisFebruary 7, 2025 | businesswire.comNew England Journal of Medicine publishes new data for Roche's Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritisFebruary 7, 2025 | globenewswire.comGenentech : FDA Approves Susvimo For Diabetic Macular Edema TreatmentFebruary 6, 2025 | markets.businessinsider.comRoche announces FDA approves Susvimo to treat DMEFebruary 4, 2025 | markets.businessinsider.comRoche's Susvimo gets FDA approval for diabetic macular edemaFebruary 4, 2025 | msn.comFDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindnessFebruary 4, 2025 | finance.yahoo.comFDA Approves Genentech's Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related BlindnessFebruary 4, 2025 | businesswire.comFDA approves Roche's Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindnessFebruary 4, 2025 | globenewswire.comRoche Holding AG (OTCMKTS:RHHBY) Shares Sold by Beach Investment Counsel Inc. PABeach Investment Counsel Inc. PA decreased its holdings in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 17.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,560 shares of the company's stock after selling 12,380 sharesFebruary 4, 2025 | marketbeat.comRoche stock target raised to CHF265 at Deutsche BankFebruary 4, 2025 | msn.comRoche (OTCMKTS:RHHBY) Upgraded at Sanford C. BernsteinSanford C. Bernstein upgraded shares of Roche to a "strong-buy" rating in a research report on Thursday.February 1, 2025 | marketbeat.comPharma Stock Roundup: SNY and RHHBY's Q4 Earnings & MoreJanuary 31, 2025 | msn.comRoche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 ProgressJanuary 31, 2025 | seekingalpha.comRoche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTUJanuary 31, 2025 | globenewswire.comRoche Holding AG (RHHBF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...January 31, 2025 | gurufocus.comRoche FY24 Core Operating Profit Rises; Sales Up 7% At CERJanuary 30, 2025 | markets.businessinsider.com Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address RHHBY Media Mentions By Week RHHBY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RHHBY News Sentiment▼0.750.70▲Average Medical News Sentiment RHHBY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RHHBY Articles This Week▼177▲RHHBY Articles Average Week Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies China Construction Bank News EssilorLuxottica Société anonyme News Airbus News Nintendo News Iberdrola News BNP Paribas News Atlas Copco News Vinci News Compass Group News Bayerische Motoren Werke Aktiengesellschaft News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RHHBY) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBefore it hits CNBC: AI was just the warm-up act (see his next prediction)During a routine analysis of my proprietary data, something caught my eye. A small American tech company with ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RHHBY Stock Alerts